LYNBROOK, N.Y., Nov. 3, 2009 (GLOBE NEWSWIRE) -- IPOdesktop.com, in a continuation of its Internet radio interviews featuring BioSpecifics Technologies Corp. (Nasdaq:BSTC), today features an interview with Dr. Eugene Wolf. Dr. Wolf is based in San Francisco, and is a board certified orthopedic surgeon who has practiced in the Bay area for the past 30 years. In the interview, Dr. Wolf says that XIAFLEX may have broad applications within his area of specialization, particularly in frozen shoulder and knee surgery, where XIAFLEX has the potential to shorten the entire healing process.

BioSpecifics is a biopharmaceutical company involved in the development of injectable collagenase for multiple indications. Dr. Wolf was interviewed by IPOdesktop.com editor Francis Gaskins.

The program can be accessed through the following link: http://www.stoxrox.com/bstc-wolf.mp3

In the interview, Dr. Wolf says that he first became interested in orthopedic surgery while attending the University of Bordeaux's medical school in France.

Following his internship in a hospital in Martinique related to the University of Bordeaux, Dr. Wolf completed his orthopedic residency at the National Orthopedic Hospital in Arlington, Virginia. Over the past 30 years, Dr. Wolf says, one of the most common side effects in post surgical treatment in his area of specialization is stiffness in the shoulders and knees. Treatment for this is estimated in the billions of dollars annually.

Dr. Wolf says he has been following the development of XIAFLEX for more than five years. He looks forward to the day when orthopedic doctors can utilize XIAFLEX injectable collagenase to help break down collagen scars, help regain motion more quickly, and prevent re-occurrence of painful side effects.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. has announced the acceptance of the Biologic License Application (BLA) and Priority Review by the U.S. Food and Drug Administration for injectable collagenase XIAFLEX in the treatment of Dupuytren's disease. Pfizer, Inc. is responsible for marketing the XIAFLEX product in Europe.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding the company's strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, its expected revenue growth, and any other statements containing the words "believes", "expects", "anticipates", "plans", "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause its actual results to differ materially from those indicated by such forward-looking statements, including the ability of its partner Auxilium to obtain regulatory approval of XIAFLEX(TM) in the United States for Dupuytren's disease and Peyronie's disease, the preparedness of Auxilium for the commercial launch of XIAFLEX(TM) for the treatment of Dupuytren's disease and the ability of Pfizer to obtain regulatory approval of XIAFLEX(TM) in its territory for these same indications, which will determine the amount of milestone, royalty and sublicense income payments it may receive; the amount of earn out payments it may receive from DFB Biotech Inc. and its affiliates; whether Auxilium exercises its option under the companies' license agreement for additional indications; the potential benefits of its existing license and development agreements; its estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the Company's Form 10-K for the year ended December 31, 2008 and the Form 10-Q for the quarter ended March 31, 2009 and any subsequent reports filed with the SEC. The Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

CONTACT:  Investor Relations Network
          Tom Gavin
          951-845-1112